Centro de Investigaciones en Microbiología y Biotecnología-UR (CIMBIUR), Facultad de Ciencias Naturales, Universidad del Rosario, Bogotá, Colombia.
Department of Pathology, Molecular and Cell-Based Medicine, Laboratory of Microbiology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
J Med Virol. 2021 May;93(5):2566-2568. doi: 10.1002/jmv.26823. Epub 2021 Feb 9.
As the coronavirus disease 2019 pandemic keep tackling global public health systems worldwide. The severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) genome keeps mutating. In that regard, the recent emergence of the B.1.1.7 lineage in the UK has called the attention of global authorities. One point of concern is that if this lineage can be detected by traditional molecular schemes for SARS-CoV-2 detection. Herein, we showed that this lineage does not affect the Berlin-Charité protocol but can challenge the available commercial kits directed to the Spike (S) gene. All efforts should be made to continue to monitor SARS-CoV-2 genomes for potential variants that can impair diagnostic testing and lead to false negative results.
随着 2019 年冠状病毒病大流行为全球公共卫生系统带来挑战,严重急性呼吸系统综合症冠状病毒 2(SARS-CoV-2)的基因组不断发生突变。在这方面,英国最近出现的 B.1.1.7 谱系引起了全球当局的关注。令人关注的一点是,如果这种谱系可以通过传统的 SARS-CoV-2 检测分子方案检测到。在此,我们表明该谱系不会影响柏林-沙里泰协议,但可能会对针对刺突(S)基因的现有商业试剂盒构成挑战。应尽一切努力继续监测 SARS-CoV-2 基因组,以发现可能影响诊断检测并导致假阴性结果的潜在变异。